glp 1 intermittent fasting Danger! The truth about on a GLP-1 You probably shouldn't do intermittent

If the program is approved and implemented, weight-loss drug coverage would begin in January 2027

Polysomnography is the gold standard for evaluating sleep by using physiologic data

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026

Its effectiveness depends on proper dosing and medical supervision to ensure safe absorption and consistent results